Dyslipidemias as rare diseases

Area of Science:

• Medical Genetics
• Endocrinology
• Cardiovascular Medicine

Background:

• Dyslipidemias are often common but can also be rare, genetically determined disorders.
• Focus on three rare dyslipidemias with new, prognosis-altering therapies: Homozygous Familial Hypercholesterolemia, Lipodystrophies, and Familial Chylomicronemia.
• These conditions, though rare, necessitate early diagnosis and specialized management.

Purpose of the Study:

• To review recent therapeutic advancements for three specific rare dyslipidemias.
• To highlight how novel treatments significantly improve patient outcomes.
• To emphasize the importance of early detection and interdisciplinary collaboration.

Main Methods:

• Review of current literature on rare genetic dyslipidemias.
• Analysis of new therapeutic agents and their impact on disease prognosis.
• Discussion of diagnostic and management strategies.

Main Results:

• Homozygous Familial Hypercholesterolemia: New drugs (evinacumab, lomitapide) improve prognosis by lowering LDL cholesterol and preventing early cardiovascular disease.
• Lipodystrophies: Metreleptin therapy effectively manages metabolic complications associated with adipose tissue loss.
• Familial Chylomicronemia: Volanesorsen reduces triglyceride levels, decreasing the risk of potentially fatal acute pancreatitis.

Conclusions:

• Novel therapies offer significant improvements for patients with rare genetic dyslipidemias.
• Early diagnosis and prompt, interdisciplinary management are critical for optimizing patient care and outcomes.
• Continued research and awareness are essential for addressing these challenging conditions.